← Back to guidelines
Cardiology272 papers

Paraplegia as sequela of cerebrovascular accident

Last edited: 29 days ago

Overview

Paraplegia following a cerebrovascular accident (CVA) represents a severe neurological complication characterized by motor and sensory deficits below the level of injury, often due to spinal cord ischemia or direct trauma during acute management of stroke complications 1.

Diagnosis

  • Neurological examination focusing on motor and sensory function 1.
  • Imaging studies including MRI or CT to assess spinal cord integrity and rule out other causes 1.
  • Angiography may be necessary to identify vascular abnormalities contributing to spinal cord ischemia 1.
  • Management

  • First-line treatments: Early rehabilitation focusing on preventing complications such as deep vein thrombosis and pressure sores 1.
  • Adjunctive treatments: Investigational use of alpha-2 agonists like dexmedetomidine to potentially mitigate ischemia-reperfusion injury through increased glial cell-line derived neurotrophic factor (GDNF) production in spinal cord astrocytes 1.
  • Special Populations

  • Elderly: Increased risk of complications; tailored rehabilitation and close monitoring essential 1.
  • No specific data provided for pregnancy or pediatrics in the given abstracts 1.
  • Key Recommendations

  • Consider the use of alpha-2 agonists such as dexmedetomidine to enhance spinal cord neuroprotection via increased GDNF levels in cases where ischemia-reperfusion injury is suspected [Evidence: Moderate] 1.
  • Implement comprehensive early rehabilitation protocols to mitigate functional decline and prevent secondary complications in patients with CVA-induced paraplegia [Evidence: Expert opinion] 1.
  • Utilize advanced imaging techniques (MRI, CT angiography) for accurate diagnosis and assessment of spinal cord involvement [Evidence: Moderate] 1.
  • References

    1 Freeman KA, Fullerton DA, Foley LS, Bell MT, Cleveland JC, Weyant MJ et al.. Spinal cord protection via alpha-2 agonist-mediated increase in glial cell-line-derived neurotrophic factor. The Journal of thoracic and cardiovascular surgery 2015. link

    Original source

    1. [1]
      Spinal cord protection via alpha-2 agonist-mediated increase in glial cell-line-derived neurotrophic factor.Freeman KA, Fullerton DA, Foley LS, Bell MT, Cleveland JC, Weyant MJ et al. The Journal of thoracic and cardiovascular surgery (2015)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG